Table 8.
Agents used in drug-eluting stents [21].
| Antineoplastics and Anti-Inflammatory Immunomodulators |
Antiproliferative | Migration Inhibitors and ECM Modulators | Enhanced Healing and Re-Endothelialization Factors |
|---|---|---|---|
| Sirolimus | QP-2, Taxol (Paclitaxel) |
Batimastat | BCP671 |
| Tacrolimus | Actinomycin | Prolyl hydroxylase inhibitors | VEGF |
| Everolimus | Methotrexate | Halofuginone | Estradiols |
| Leflunomide | Angiopeptin | C-proteinase inhibitors | NO donor compounds |
| M-Prednisolone | Vincristine | Probucol | EPC antibodies |
| Dexamethasone | Mitomycin | Biorest | |
| Interferon r-1b | Statins | ||
| Mycophenolic acid | C-myc antisense | ||
| Mizoribine | Abbott ABT-578 | ||
| Cyclosporine | Resten ASE | ||
| Tranilast | 2-chloro-deoxyadenosine PCNA ribozyme |
ECM: extracellular matrix, EPC: endothelial progenitor cells, NO: nitric oxide, PCNA: proliferating cell nuclear antigen, VEGF: vascular endothelial growth factor, and QP-2: 7-hexanoyltaxol.